electroCore Raises 2026 Revenue Growth Outlook to Over 30% After Q2 Beat on Bottom Line
ECOR sits 61% above its 52-week low of $4.16.
Summary
electroCore posted Q2 revenue of $9.45M, a 28% YoY jump but just shy of the $9.49M consensus. The miss is negligible; more importantly, operating income and pretax loss both came in better than expected. Management raised full-year 2026 revenue growth guidance to over 30%, up from prior expectations, and now sees positive Adjusted EBITDA in Q3 2027. Growth is driven by VA channel prescription sales and the Quell Fibromyalgia product. This follows a Q1 where the company flagged going-concern doubts, making the raised guidance and path to profitability a meaningful positive signal. The stock, with a ~$60M market cap, could react sharply to the improved outlook.
At the time of this announcement, ECOR was trading at $6.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $60.4M. The 52-week trading range was $4.16 to $10.50. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.